Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 4:36 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 390 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: ZILRETTA Clear all

Conditions: Breast Cancer
Interventions: cyclophosphamide, docetaxel, doxorubicin hydrochloride, Trastuzumab, Carboplatin, Paclitaxel; Drug · Biological
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Osteoarthritis of the Knee
Interventions: FX006 32 mg, TCA IR 40; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 40 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 4
States / cities: Canoga Park, California • San Diego, California • Hialeah, Florida + 1 more

Conditions: Shoulder Pain
Interventions: Methylprednisolone (MPA), Triamcinolone Acetonide (TA); Drug
Lead sponsor: Campbell Clinic; Other
Eligibility: 18 Years to 99 Years
Enrollment: 421 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Germantown, Tennessee

Conditions: Melanoma
Interventions: Ipilimumab, Corticosteroid: Betamethasone, Corticosteroid: Dexamethasone, Corticosteroid: Fludrocortisone, Corticosteroid: Hydrocortisone, Corticosteroid: Meprednisone, Corticosteroid: Methylprednisolone, Corticosteroid: Prednisolone, Corticosteroid: Prednisone, Corticosteroid: Triamcinolone; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 16 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 14
States / cities: Scottsdale, Arizona • Duarte, California • Los Angeles, California + 11 more

Conditions: Breast Cancer
Interventions: Docetaxel, Doxorubicin, Cyclophosphamide; Drug
Lead sponsor: US Oncology Research; Industry
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 1,961 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2020
U.S. locations: 95
States / cities: Birmingham, Alabama • Phoenix, Arizona • Sedona, Arizona + 85 more

Conditions: Osteoarthritis, Knee
Interventions: FX006 32 mg; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 40 Years and older
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 9
States / cities: El Cajon, California • La Mesa, California • Pomona, California + 5 more

Conditions: Gout Attack
Interventions: Etanercept, Triamcinolone Acetonide; Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years to 85 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Acute Leukemia, Myelodysplastic Syndrome, Myeloproliferative Disorders
Interventions: ATG dosing platform when combined with standard tacrolimus and mini methotrexate; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 75 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Glaucoma
Interventions: Triamcinolone injection, sub-tenon; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 2
States / cities: San Jose, California • Stanford, California

Conditions: Uveitis
Interventions: Daclizumab; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: Not listed
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cataract
Interventions: intraocular triamcinolone and gatifloxicin; Drug
Lead sponsor: Dean Health System; Other
Eligibility: 40 Years to 80 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Baraboo, Wisconsin

Conditions: Osteoarthritis, Tendinopathy, Arthropathy
Interventions: Triamcinolone injection to the shoulder, elbow, wrist, or hand, Ketorolac injection to the shoulder, elbow, wrist, or hand; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 4
States / cities: Atlanta, Georgia

Conditions: Neovascular Age-related Macular Degeneration
Interventions: Aflibercept, Triamcinolone Acetonide, Verteporfin; Drug
Lead sponsor: Duke University; Other
Eligibility: 55 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Bursitis
Interventions: Kenalog; Drug
Lead sponsor: West Virginia University; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Vitiligo
Interventions: Needling, Triamcinolone; Procedure · Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years to 89 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Somerset, New Jersey

Conditions: Knee Osteoarthritis, Musculoskeletal Disease, Surgery
Interventions: PAI, PAI + steroid, PAI + zilretta; Drug
Lead sponsor: Walter Reed National Military Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Knee Osteoarthritis
Interventions: Zilretta; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 30 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Uterine Fibroids, Adenomyosis
Interventions: Triamcinolone, Bupivacaine, Iohexol contrast; Drug · Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 30 Years to 60 Years · Female only
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: Westwood, Los Angeles, California • Chapel Hill, North Carolina

Conditions: Knee Osteoarthritis
Interventions: Embosphere Microspheres, Corticosteroid injection; Device · Drug
Lead sponsor: Merit Medical Systems, Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 19
States / cities: Long Beach, California • Washington D.C., District of Columbia • Atlanta, Georgia + 15 more

Conditions: Humeral Fractures
Interventions: kenalog, Lidocaine; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 90 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Osteoarthritis of the Knee
Interventions: FX006, TCA IR; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 40 Years and older
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 2
States / cities: Tucson, Arizona • Duncansville, Pennsylvania

Conditions: HTLV-I Infection, T Cell Leukemia
Interventions: daclizumab; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 10 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Nerve Block, Pain, Postoperative, Pelvic Floor Disorders, Pelvic Organ Prolapse, Pudendal Neuralgia, Surgery
Interventions: Pudendal block; Procedure
Lead sponsor: MetroHealth Medical Center; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Acne Keloidalis Nuchae, NdYag Laser, AKN, Acne Keloidalis, AK, Dermatitis Papillaris Capillitii, Folliculitis Keloidalis Nuchae, Sycosis Nuchae, Acne Keloid, Keloidal Folliculitis, Lichen Keloidalis Nuchae, Folliculitis Nuchae Scleroticans, Sycosis Framboesiformis
Interventions: NdYag Laser(hair removal laser) plus topical corticosteroid, Topical corticosteroid alone; Device · Drug
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Detroit, Michigan

Search by objective public record fields.

Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer

Study to Characterize the PK and Local Extent and Duration of Exposure From FX006 in Patients With OA of the Knee

Pain Increases After Shoulder Injection

Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases

TAC Versus TC for Adjuvant Breast Cancer

Study to Evaluate the Effect of FX006 on Synovial Inflammation in Patients With OA of the Knee

Pilot Study Evaluating The Efficacy Of Etanercept In Acute Gout

Trial of 2 Step ATG for Prevention of Acute GVHD Post Allogeneic Stem Cell Transplant

Post-Operative Sub-Tenon Kenalog in Glaucoma Filtering Surgery

Daclizumab Injections to Treat Non-Infectious Sight-Threatening Uveitis

Intraocular Steroid After Cataract Surgery Study

Ketorolac in Upper Extremity Tendinopathy and Arthropathy

Adjunctive Photodynamic Therapy + Aflibercept vs. Afilbercept Alone for PDA in NV AMD

Comparison of Steroid Dosages on the Efficacy of Trochanteric Bursa Injection

Assessing the Efficacy of Needling With or Without Corticosteroids in the Repigmentation of Vitiligo

Use of Corticosteroid in Intraopertive Injections in Total Knee Replacement Surgery.

The Effect of Intra-articular Bilateral Knee Injections of Zilretta on Performance Measures in Adults With Knee OA

Effect of Addition of Steroids on Duration of Analgesia

GAE Using Embosphere Microspheres vs Corticosteroid Injections for Treatment of Symptomatic Knee OA (MOTION)

Glenohumeral Cortisone Injection

Study of FX006 in Patients With Osteoarthritis of the Knee

Anti-Tac for Treatment of Leukemia

Pudendal Nerve Block in Vaginal Surgery

NdYag Laser for Acne Keloidalis Nuchae